Budget 2026 slashes customs duties on 17 cancer drugs, eases baggage rules

The Union Budget 2026-27, a pivotal annual financial statement, has introduced significant reforms in India's customs regime, marking a shift towards a more facilitative and public-centric approach. These changes, particularly the waiver of customs duty on 17 specific cancer drugs and the easing of personal baggage rules, reflect the government's dual focus on public welfare and enhancing ease of business and travel. **Background Context and What Happened:** Customs duties are taxes levied on goods imported into a country. Traditionally, they serve multiple purposes: generating revenue for the government, protecting domestic industries from foreign competition, and regulating trade. However, in specific sectors like healthcare, high customs duties can make essential goods, such as life-saving medicines, prohibitively expensive. India faces a substantial burden of non-communicable diseases, with cancer being a leading cause of mortality and significant financial strain on families. Recognizing this, there has been a persistent demand from patient advocacy groups and the medical community to reduce the cost of cancer treatment, a significant portion of which is attributed to imported drugs. In response, the Union Budget 2026-27 announced a complete waiver of customs duty on 17 specific cancer drugs. This move is a direct intervention to make these critical medicines more affordable and accessible to patients across the country. Simultaneously, the budget addressed another common pain point for citizens: personal baggage rules. Historically, these rules, along with associated duties, have often been perceived as cumbersome. The new budget simplifies these rules, reducing the duty on goods for personal use to a standardized 10 percent. Furthermore, it envisages a 'trust-based customs regime' complemented by a single-window system and AI integration, aiming to streamline import and export processes, reduce human intervention, and enhance transparency and efficiency. **Key Stakeholders Involved:** Several stakeholders are directly impacted by these budgetary provisions. The **Government of India**, particularly the **Ministry of Finance** and the **Central Board of Indirect Taxes and Customs (CBIC)**, is the primary driver and implementer of these policies. **Cancer patients and their families** are perhaps the most significant beneficiaries of the drug duty waiver, as it promises to alleviate their financial burden. **Pharmaceutical companies**, both domestic manufacturers and importers, will experience changes in their cost structures and market dynamics. While importers of the 17 exempted drugs will see reduced costs, domestic manufacturers might face increased competition from cheaper imported alternatives, though this could also spur innovation. **Indian citizens traveling abroad** and **Non-Resident Indians (NRIs)** stand to benefit from the eased baggage rules, making international travel less complicated and more cost-effective. Lastly, **customs officials** will see their roles evolve with the integration of AI and a single-window system, moving towards more data-driven and less discretionary processing. **Significance for India:** These reforms carry profound significance for India. From a **social perspective**, the waiver on cancer drugs is a major step towards realizing the 'Right to Health,' which, though not explicitly stated, is implicitly guaranteed under **Article 21 (Right to Life and Personal Liberty)** of the Indian Constitution. It aligns with the objectives of the **National Health Policy** to ensure equitable access to affordable healthcare. By reducing treatment costs, it can significantly improve health outcomes and reduce catastrophic health expenditures for millions. **Economically**, while the customs duty waiver might lead to a marginal revenue loss for the government, the broader benefits in public health and productivity outweigh this. The move could also stimulate the import of advanced cancer therapies, potentially exposing Indian doctors to newer treatments. The easing of baggage rules is expected to boost international travel and consumption, potentially benefiting the tourism and retail sectors. The shift to a trust-based, AI-integrated customs regime reflects India's commitment to improving its 'Ease of Doing Business' ranking and leveraging technology for better governance, a core tenet of the 'Digital India' initiative. **Historical Context and Future Implications:** India has a history of using customs duties as a tool for economic management and social welfare. Previous budgets have often seen rationalization of duties on various goods, but a specific, targeted waiver for a critical disease like cancer underscores a growing focus on public health. The push for a trust-based system builds upon earlier efforts to simplify tax regimes and reduce bureaucratic hurdles, drawing parallels with the introduction of the Goods and Services Tax (GST) which aimed to create a unified indirect tax structure. Looking ahead, the success of the AI-integrated single-window system will be crucial. It could set a precedent for further digitalization and simplification across other government services. There might be calls to extend similar duty waivers to other life-saving drugs or medical equipment for various diseases. The impact on domestic pharmaceutical R&D needs careful monitoring; while immediate affordability is achieved, sustained reliance on imports could potentially disincentivize local innovation. The eased baggage rules could be a precursor to further liberalization in personal import policies, fostering greater international exchange and consumption. Overall, these reforms signal a proactive government approach to balancing revenue generation with public welfare and modernizing administrative processes for a more efficient and citizen-friendly India. The legal framework for these changes primarily stems from the **Customs Act, 1962**, which empowers the government to levy and exempt duties, and the annual **Finance Act**, which enacts the budgetary proposals into law as per **Article 265** of the Constitution, stating that no tax shall be levied or collected except by authority of law. The budget itself is presented under **Article 112 (Annual Financial Statement)**.